TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15483780

Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.8 g/kg/day) for diabetic patients
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g/kg/day) for nondiabetic patients
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Low-protein diet for both diabetic and nondiabetic patients
Number of subjects: 169

Group type: COMPARATOR
Intervention: Free protein diet for diabetic patients
Number of subjects: 169

Group type: COMPARATOR
Intervention: Free protein diet for nondiabetic patients
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Low-protein diet for both groups
Number of subjects: 169
Study: 11280671

Group type: EXPERIMENTAL
Intervention: Salbutamol (100 microg/puff) with low inspiratory flow rate (0.6 l/s)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol (100 microg/puff) with high inspiratory flow rate (1.2 l/s)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no specific control intervention mentioned)
Number of subjects: 10
Study: 9470565

Group type: EXPERIMENTAL
Intervention: Tartar-control dentifrice (containing tetrapotassium pyrophosphate, PEG‐6, disodium pyrophosphate, and tetrasodium pyrosulphate in a 5.0% soluble pyrophosphate formulation)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Regular dentifrice (control group)
Number of subjects: 38
Study: 7930696

Group type: EXPERIMENTAL
Intervention: CD4-PE40 at 40, 80, or 160 micrograms/m2
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CD4-PE40 at 80 micrograms/m2
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CD4-PE40 infusions
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CD4-PE40
Number of subjects: 21
Study: 3150630

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TST) plus chemotherapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 51
Study: 30445939

Group type: EXPERIMENTAL
Intervention: Working for You intervention (adapted from Be Fit Be Well) using automated SMS text messaging for delivery.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Be Fit Be Well (original intervention)
Number of subjects: 0
Study: 27573562

Group type: EXPERIMENTAL
Intervention: Pictilisib (260 mg daily on days 1-5 every week) with paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo with paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle)
Number of subjects: 183
Study: 26571324

Group type: EXPERIMENTAL
Intervention: Thermal balancing therapy using a Therapeutic Device for 6 months
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 124
Study: 23536000

Group type: EXPERIMENTAL
Intervention: SU11274
Number of subjects: 80

Group type: COMPARATOR
Intervention: c-Met expression
Number of subjects: 80
Study: 20373114

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Somatostatin (high-dose infused over 12 h)
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Somatostatin (bolus)
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Somatostatin (pancreatic duct injection)
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Somatostatin (biliary sphincterotomy)
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Somatostatin (intention-to-treat analysis)
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Octreotide (high-dose)
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Octreotide (pancreatic duct injection)
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Octreotide (biliary sphincterotomy)
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Octreotide (intention-to-treat analysis)
Number of subjects: 3818
Study: 18442357

Group type: EXPERIMENTAL
Intervention: Isoflavone-intact soya protein (active treatment)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Isoflavone-free placebo (control)
Number of subjects: 71
Study: 15722803

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention and preventive physical therapy
Number of subjects: 185

Group type: COMPARATOR
Intervention: Minimal Treatment Group (examination, reassurance, and activity advice)
Number of subjects: 185
Study: 12666111

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate 10 gm daily
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 10390133

Group type: COMPARATOR
Intervention: High milk consumption
Number of subjects: 594

Group type: COMPARATOR
Intervention: High cheese consumption
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Low milk consumption
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Low cheese consumption
Number of subjects: 594

Group type: COMPARATOR
Intervention: Meat or fish intake
Number of subjects: 594
Study: 8558219

Group type: COMPARATOR
Intervention: CMFVP (cyclophosphamide 60 mg/m2/d by mouth for 1 year, methotrexate 15 mg/m2 intravenously weekly for 1 year, fluorouracil 400 mg/m2 intravenously weekly for 1 year, vincristine 0.625 mg/m2 intravenously weekly for the first 10 weeks, and prednisone weeks 1 to 10 with doses decreasing from 30 mg/m2 to 2.5 mg/m2)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: CMFVP plus bilateral ovariectomy
Number of subjects: 314

Group type: COMPARATOR
Intervention: CMFVP/CMFVP plus ovariectomy
Number of subjects: 314
Study: 2056783

Group type: EXPERIMENTAL
Intervention: sucralfate (1g/6h)
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 6650108

Group type: EXPERIMENTAL
Intervention: Brief courses of antibiotics active against major contaminating bacterial pathogens given prior to surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term administration of antibiotics after surgery
Number of subjects: 0
Study: 30845363

Group type: EXPERIMENTAL
Intervention: Inpatient physical activity (PA) monitoring
Number of subjects: 389
Study: 29324539

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone intervention (Optimal Personalised Care After Treatment-Gynaecological)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual hospital-based follow-up (Control)
Number of subjects: 24
Study: 27651394

Group type: EXPERIMENTAL
Intervention: Psychoeducational self-management program
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group (general psychosocial information)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 540
Study: 24435063

Group type: EXPERIMENTAL
Intervention: Remote personalized risk communication intervention (TeleCARE)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Generic print control condition
Number of subjects: 272
Study: 23031619

Group type: EXPERIMENTAL
Intervention: Yearly mammography and clinical breast examination (Group 1)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Yearly MRI and clinical breast examination, and biennial mammography (Group 2)
Number of subjects: 2000
Study: 20151052

Group type: COMPARATOR
Intervention: Behavioural therapy
Number of subjects: 3647

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 3647
Study: 17414467

Group type: EXPERIMENTAL
Intervention: Accelerated multimodality treatment program including a 12-day induction course of radiation (1.5 Gy twice daily to a total of 30 Gy) concurrent with continuous intravenous infusions of cisplatin (20 mg/m2 per day) and 5-fluorouracil (1000 mg/m2 per day), followed by surgery and a second course of chemoradiotherapy.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Accelerated multimodality treatment program
Number of subjects: 93
Study: 15114104

Group type: EXPERIMENTAL
Intervention: Histidine-tryptophan-ketoglutarate (HTK) solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both HTK and UW solutions
Number of subjects: 20
Study: 11599601

Group type: COMPARATOR
Intervention: Marinol (15 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Smoked THC (16.88 mg) in a placebo marijuana cigarette
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Smoked marijuana (2.11% THC and 0.12% THCV)
Number of subjects: 4
Study: 10984320

Group type: EXPERIMENTAL
Intervention: Sex hormone substitution therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Turner syndrome patients
Number of subjects: 21
Study: 8055724

Group type: EXPERIMENTAL
Intervention: Toradol (ketorolac tromethamine) injected into the sphincter muscle and taken orally for five days postoperatively
Number of subjects: 63

Group type: COMPARATOR
Intervention: Narcotics (intramuscular/oral analgesics) after overnight hospital stay
Number of subjects: 63

Group type: COMPARATOR
Intervention: SQMP (subcutaneous infusion of morphine sulfate via home infusion pump)
Number of subjects: 63
Study: 2662688

Group type: EXPERIMENTAL
Intervention: Doxycycline + Tinidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxycycline alone
Number of subjects: 0
Study: 233889

Group type: EXPERIMENTAL
Intervention: Saturated free fatty acids (C3 to C18) applied daily under occlusive patch tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linoleic acid (C18 unsaturated fatty acid) applied daily under occlusive patch tests
Number of subjects: 0
Study: 31937325

Group type: EXPERIMENTAL
Intervention: Highest healthy lifestyle score (HLS)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Highest healthy lifestyle score (HLS) in postmenopausal women
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Highest Healthy Eating Index score (HEI)
Number of subjects: 1050
Study: 30153126

Group type: EXPERIMENTAL
Intervention: Deep local anesthesia (group D)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Subcutaneous local anesthesia (group S)
Number of subjects: 68
Study: 28419149

Group type: EXPERIMENTAL
Intervention: Automated SMS health promotions and reminders
Number of subjects: 181
Study: 24292979

Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) combined with microfracture surgery (n=19)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Microfracture surgery alone (Control group, n=16)
Number of subjects: 35
Study: 24672620

Group type: EXPERIMENTAL
Intervention: Compressor-administered defibrillation
Number of subjects: 197

Group type: COMPARATOR
Intervention: Facilitator-administered defibrillation
Number of subjects: 197
Study: 22959807

Group type: EXPERIMENTAL
Intervention: Temoporfin mediated photodynamic therapy (PDT) - Arm A: 0.15 mg/kg Foscan; 96 h drug-light interval
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Temoporfin mediated photodynamic therapy (PDT) - Arm B: 0.10 mg/kg; 48 h drug-light interval
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Temoporfin mediated photodynamic therapy (PDT) - Arm C: 0.075 mg/kg; 24 h drug-light interval
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Temoporfin mediated photodynamic therapy (PDT) - All arms
Number of subjects: 22
Study: 19374210

Group type: EXPERIMENTAL
Intervention: 2.5 ml of hyperbaric S75:R25 bupivacaine (10 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3 ml of hyperbaric S75:R25 bupivacaine (12 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4 ml of hyperbaric S75:R25 bupivacaine (16 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5 ml of hyperbaric S75:R25 bupivacaine (20 mg)
Number of subjects: 40
Study: 17542833

Group type: EXPERIMENTAL
Intervention: Air humidification active
Number of subjects: 71

Group type: COMPARATOR
Intervention: Air humidification inactive (Control)
Number of subjects: 71
Study: 15464314

Group type: EXPERIMENTAL
Intervention: Actinomycin D-coated Multilink-Tetra stent (2.5 or 10 microg/cm(2))
Number of subjects: 360

Group type: COMPARATOR
Intervention: Metallic stent (MS)
Number of subjects: 360
Study: 11553222

Group type: EXPERIMENTAL
Intervention: Gastric interponats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colon interponats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posterior mediastinal reconstruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anterior mediastinal reconstruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various interponats and routes of reconstruction
Number of subjects: 0
Study: 9805322

Group type: EXPERIMENTAL
Intervention: Right-sided contractions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Left-sided contractions
Number of subjects: 0
Study: 8582461

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg at 10:00 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg at 22:00 h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo at 10:00 h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo at 22:00 h
Number of subjects: 12
Study: 2206038

Group type: EXPERIMENTAL
Intervention: Fructans (FAs) isolated from Jerusalem artichokes, 20 g dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fructans (FAs) added to a wheat-starch meal, 10 g FA with 50 g wheat-starch
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fructose ingestion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 8
Study: 209710

Group type: EXPERIMENTAL
Intervention: Four-drug combination chemotherapy (vincristine, CCNU, cyclophosphamide, methotrexate)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Three-drug combination chemotherapy (CCNU, cyclophosphamide, methotrexate)
Number of subjects: 109
Study: 29521573

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*04:01
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*07:01
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: HLA region variants
Number of subjects: 941
Study: 26996291

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Watchful Waiting
Number of subjects: 287
Study: 24910951

Group type: EXPERIMENTAL
Intervention: Eccentric-overload training program (half-squat and leg-curl exercises using flywheel ergometers)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Eccentric-overload training program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 36
Study: 24674827

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with 1.0 g cefazolin intravenously 30 minutes before incision
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo with equal volume of sterile saline
Number of subjects: 200
Study: 22686549

Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST) intervention group
Number of subjects: 129

Group type: COMPARATOR
Intervention: Education-only control group
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Care recipients in PST group
Number of subjects: 129

Group type: COMPARATOR
Intervention: Care recipients in control group
Number of subjects: 129
Study: 19576549

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 0
Study: 17300420

Group type: EXPERIMENTAL
Intervention: Psychological therapy
Number of subjects: 223
Study: 15117570

Group type: EXPERIMENTAL
Intervention: 0.1% pemirolast potassium ophthalmic solution dosed twice daily (b.i.d.)
Number of subjects: 169

Group type: COMPARATOR
Intervention: 0.1% pemirolast potassium ophthalmic solution dosed four times daily (q.i.d.)
Number of subjects: 169
Study: 11442160

Group type: EXPERIMENTAL
Intervention: Lateralized postictal EEG delta activity (PPDA)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 29
Study: 9834566

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori detection via rapid urease test
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori detection via CLO test
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori detection via histopathological examination
Number of subjects: 26

Group type: COMPARATOR
Intervention: Helicobacter pylori culture
Number of subjects: 26
Study: 8129435

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 100 mg/kg intravenously followed by a single dose of 50 mg/kg 24 hours later
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chloramphenicol 40 mg/kg intravenously, then 25 mg/kg eight hourly for five days
Number of subjects: 55
Study: 1719197

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-molecular-weight dextran
Number of subjects: 24

Group type: COMPARATOR
Intervention: Negative controls (diagnostic laparoscopy)
Number of subjects: 24
Study: 379936

Group type: EXPERIMENTAL
Intervention: Levamisole (3 days every 2 weeks, 1.1-3.8 mg/kg per day, fixed dose of 3 x 50 mg)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 31362572

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 31614871

Group type: EXPERIMENTAL
Intervention: Variable practice group (n = 10) - practiced at five different distances (3.35, 3.96, 4.57, 5.18, and 5.79 m) for 100 shots per day.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Constant practice group (n = 10) - practiced only at a free throw distance of 4.57 m for 100 shots per day.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (constant and variable practice)
Number of subjects: 20
Study: 27784046

Group type: EXPERIMENTAL
Intervention: PGA mesh intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no PGA mesh)
Number of subjects: 97
Study: 25172584

Group type: EXPERIMENTAL
Intervention: Resurfacing hip arthroplasty (RHA)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cementless 28‐mm metal‐on‐metal (MoM) total hip arthroplasty (THA)
Number of subjects: 71
Study: 23498306

Group type: COMPARATOR
Intervention: Paroxetine (PRX) alone (n = 48)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA, n = 54)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Electrical acupuncture (EA, n = 58)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Electrical acupuncture (EA)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA)
Number of subjects: 160
Study: 21444007

Group type: EXPERIMENTAL
Intervention: Single-row (SR) suture anchor repair
Number of subjects: 71

Group type: COMPARATOR
Intervention: Double-row (DR) suture anchor repair
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both SR and DR groups
Number of subjects: 71
Study: 19786683

Group type: EXPERIMENTAL
Intervention: e‐prescribing system
Number of subjects: 300
Study: 16398702

Group type: EXPERIMENTAL
Intervention: NBI-6024 (five biweekly subcutaneous injections)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NBI-6024
Number of subjects: 0
Study: 17197712

Group type: EXPERIMENTAL
Intervention: Abciximab (EA) during PCI
Number of subjects: 849

Group type: COMPARATOR
Intervention: Eptifibatide (EE) during PCI
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Abciximab (EA) in patients with unstable angina
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Abciximab (EA) in patients with myocardial infarction (MI)
Number of subjects: 849
Study: 14523462

Group type: EXPERIMENTAL
Intervention: imatinib
Number of subjects: 139

Group type: COMPARATOR
Intervention: IFN/Ara-C
Number of subjects: 139
Study: 10100145

Group type: EXPERIMENTAL
Intervention: Natural IFN‐alpha
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Recombinant IFN‐alpha
Number of subjects: 16

Group type: COMPARATOR
Intervention: No IFN (Control)
Number of subjects: 16
Study: 8737437

Group type: EXPERIMENTAL
Intervention: Interactive educational workshop and managerial peer review committee
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 119
Study: 1859293

Group type: EXPERIMENTAL
Intervention: Aspirin (exact dosage not specified)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Natural history study (no specific intervention)
Number of subjects: 588
Study: 6643333

Group type: EXPERIMENTAL
Intervention: Intramuscular (im) administration of 500 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous (iv) administration of 500 mg
Number of subjects: 8
Study: 29330853

Group type: EXPERIMENTAL
Intervention: Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Facemask breathing
Number of subjects: 80
Study: 28557720

Group type: EXPERIMENTAL
Intervention: FCR checklist intervention
Number of subjects: 298
Study: 26259166

Group type: EXPERIMENTAL
Intervention: eoSim simulator
Number of subjects: 28
Study: 24057039

Group type: EXPERIMENTAL
Intervention: Single-use injection device (SID)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Handheld syringe
Number of subjects: 119
Study: 21418560

Group type: EXPERIMENTAL
Intervention: Nutrition therapy
Number of subjects: 600
Study: 18394022

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe 10 mg/10 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both treatments (Simvastatin and Simvastatin/Ezetimibe)
Number of subjects: 15
Study: 16965874

Group type: EXPERIMENTAL
Intervention: Faecal occult blood test
Number of subjects: 2987

Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy
Number of subjects: 2987
Study: 12738757

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 232

Group type: COMPARATOR
Intervention: Cyclosporin microemulsion
Number of subjects: 232
Study: 11041196

Group type: EXPERIMENTAL
Intervention: 30% body weight traction
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60% body weight traction
Number of subjects: 10

Group type: COMPARATOR
Intervention: 10% body weight traction
Number of subjects: 10
Study: 9239452

Group type: EXPERIMENTAL
Intervention: Miglitol administered via intravenous route
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miglitol administered via oral route
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated administration of miglitol to rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miglitol in pregnant rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miglitol in lactating rats
Number of subjects: 0
Study: 8452648

Group type: EXPERIMENTAL
Intervention: Combination pyrimethamine-sulfadiazine and spiramycine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Spiramycine alone
Number of subjects: 52